The New Ally Bridge Lb Healthcare Master Fund Ltd Holding in Sciclone Pharmaceuticals Inc
Ally Bridge Lb Healthcare Master Fund Ltd filed with the SEC SC 13D/A form for Sciclone Pharmaceuticals Inc. The form can be accessed here: 000119312516767104. As reported in Ally Bridge Lb Healthcare Master Fund Ltd’s form, the filler as of late owns 1.3% or 678,077 shares of the Health Care–company.
Sciclone Pharmaceuticals Inc stake is a new one for the and it was filed because of activity on November 14, 2016. We feel this shows Ally Bridge Lb Healthcare Master Fund Ltd’s positive view for the stock.
Reasons Why Ally Bridge Lb Healthcare Master Fund Ltd Bought – Sciclone Pharmaceuticals Inc Stock
PURPOSE OF TRANSACTION
Item4 of the Schedule 13D is hereby supplemented asfollows:
On November14, 2016, ABG Management Limited and its affiliates and GL Management and its affiliates, on behalf theconsortium formed pursuant to the Consortium Agreement (the “Consortium”) filed as Exhibit 7.02 to the Schedule 13D, submitted a preliminary non-binding proposal (the “Proposal”) to the board of directors of the Issuer for theacquisition of all of the outstanding share capital of the Issuer not already owned by the Consortium at US$11.18 per share of Common Stock in cash (the “Acquisition”). The Consortium intends to finance the Acquisition through acombination of debt and equity financing.
|CUSIP No. 80862K104||Page 8 of 10|
The Consortium indicated in the Proposal that it is prepared to expeditiously negotiate andfinalize the terms of the Acquisition in definitive agreements. The Proposal also provided that no binding obligation on the part of the Issuer or the Consortium shall arise with respect to the Acquisition unless and until definitive agreements havebeen executed.
If the Acquisition is completed, the Issuer’s Common Stock would become eligible for termination of registrationpursuant to Section12(g)(4) of the Act and would be delisted from the NASDAQ Global Select Market.
The summary of the Proposal inthis Amendment No.1 is not intended to be complete and is qualified in its entirety by reference to the full text of the Proposal, a copy of which is attached hereto as Exhibit 7.03.
Sciclone Pharmaceuticals Inc Institutional Sentiment
Latest Security and Exchange filings show 128 investors own Sciclone Pharmaceuticals Inc. The institutional ownership in Q3 2015 is high, at 68.25% of the outstanding shares. This is decreased by 3075290 the total institutional shares. 34839438 were the shares owned by these institutional investors. In total 13 funds opened new Sciclone Pharmaceuticals Inc stakes, 49 increased stakes. There were 26 that closed positions and 52 reduced them.
Americafirst Capital Management Llc is an institutional investor bullish on Sciclone Pharmaceuticals Inc, owning 87524 shares as of Q3 2015 for less than 0.01% of its portfolio. Ranger Investment Management Lp owns 130840 shares or 0.05% of its portfolio. CT Nantahala Capital Management Llc have 0.16% of their stock portfolio for 170218 shares. Further, Matarin Capital Management Llc reported stake worth less than 0.01% of its US stock portfolio. The CA Sensato Investors Llc owns 1564682 shares. Sciclone Pharmaceuticals Inc is 2.03% of the manager’s US portfolio.
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).
SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.
Insitutional Activity: The institutional sentiment increased to 1.18 in Q2 2016. Its up 0.06, from 1.12 in 2016Q1. The ratio improved, as 26 funds sold all SciClone Pharmaceuticals, Inc. shares owned while 41 reduced positions. 32 funds bought stakes while 47 increased positions. They now own 38.22 million shares or 3.91% more from 36.79 million shares in 2016Q1.
Kbc Nv has 0% invested in the company for 11,670 shares. Denver Investment Limited Liability Corp accumulated 10,678 shares or 0.01% of the stock. Princeton Alpha Mngmt L P holds 15,018 shares or 0.03% of its portfolio. Ativo Capital Mgmt Ltd Liability has 98,006 shares for 0.31% of their US portfolio. Gsa Capital Llp last reported 209,113 shares in the company. Hanseatic Management Services has invested 0% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Proshare Advsr Ltd Liability has invested 0.01% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Teachers Advisors holds 0% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 78,113 shares. Nationwide Fund Advsrs last reported 0% of its portfolio in the stock. Geode Management Limited Liability Com holds 346,098 shares or 0% of its portfolio. Preferred Lc accumulated 3,132 shares or 0.02% of the stock. Shinko Asset Management Ltd last reported 324,651 shares in the company. Cornerstone Capital Ltd Liability Corporation owns 271,370 shares or 0.03% of their US portfolio. Moreover, Employees Retirement Association Of Colorado has 0% invested in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 19,307 shares. Babson Capital Management Ltd Liability holds 0.01% or 17,700 shares in its portfolio.
Insider Transactions: Since August 12, 2016, the stock had 0 insider buys, and 12 insider sales for $10.10 million net activity. Zhao Hong sold 40,500 shares worth $421,605. Another trade for 7,802 shares valued at $82,837 was made by Cheung Wilson Wai-Shun on Friday, August 12. Another trade for 25,040 shares valued at $257,896 was made by CHANG NANCY T on Friday, August 26. $371,892 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) was sold by Blobel Friedhelm. 31,083 shares with value of $323,574 were sold by Meng Chuncai on Friday, August 12. 32,832 shares were sold by Xie Lan, worth $340,221. Another trade for 48,667 shares valued at $506,623 was made by King Robert on Friday, August 12.
The stock closed at $9.85 during the last session. It is down 22.20% since April 12, 2016 and is downtrending. It has underperformed by 27.18% the S&P500.
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $504.71 million. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. It has a 13.16 P/E ratio. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong.
More notable recent SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on October 28, 2009, also Prnewswire.com with their article: “SciClone Reports Third Quarter 2016 Financial Results” published on November 09, 2016, Prnewswire.com published: “SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On …” on October 25, 2016. More interesting news about SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) were released by: Quotes.Wsj.com and their article: “DOW JONES, A NEWS CORP COMPANY” published on February 12, 2011 as well as Nasdaq.com‘s news article titled: “Sciclone Pharmaceuticals Inc (SCLN) President & CEO Friedhelm Blobel Sold $5 …” with publication date: August 19, 2016.
According to Zacks Investment Research, “Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world’s most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.”
SCLN Company Profile
SciClone Pharmaceuticals, Inc. (SciClone), incorporated on June 26, 2003, is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately seven partnered and in-licensed products in China. The Firm sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.